LGND shares fell 1.5% to $314.12 as of October 29, 2026, a modest decline from the prior close of $318.78. BestStocks flagged the session as a major change for LGND. The move is tied to an earnings beat. Below, we break down what changed for LGND, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
Earnings Beat
Ligand Pharmaceuticals Incorporated (LGND) reported EPS of $2.67 vs. $2.33 consensus estimate, beating by 14.6% on 2026-10-29. LGND earnings announcement scheduled for 2026-11-05 (consensus EPS estimate $2.26).
This summary describes the catalyst and move as first detected on Oct 29, 2026, 10:08 AM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
Material / EarningsLow confidence
Rel. volume
0.4×
Below Avg
Vs peers
—
No comparable peers
Market cap
$6.3B
NASDAQ Global Market
Analyst target
$339
+8.1% vs price
Price chart
Sep 28 – Oct 29
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for LGND investors
For LGND investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Earnings beat — stock sold off (sell-the-news reaction); Positive price momentum. Weighing against that: Negative session, down 1.5%; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $339.43, implying +8.1% upside from $314.12. BestStocks rates the overall signal quality low (51/100). With earnings due imminently, the next report is the most likely near-term test of the move.
LGND price reaction
LGND last traded at $314.12, down $4.66 (-1.46%) from the previous close of $318.78. The session traded on 0.4× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $293.26 and $318.78, and it currently sits about 82% of the way up that band.
Bullish and bearish analyst opinions on LGND
◆Latest catalyst·a mixed signal
The latest catalyst — an earnings beat the stock sold off — it cuts both ways, with the event and the market's reaction pointing in different directions.
The consensus analyst price target on LGND is $339.43, 8.1% above the recent $314.12. Over the past 90 days analysts logged 0 upgrades, 5 maintains, and 0 downgrades. Here is how the bullish and bearish cases on LGND line up.
▲ The bullish case
+Wall Street's consensus price target of $339.43 implies +8.1% upside from $314.12.
+The Street's most bullish target is $358.00 (+14.0%).
+Earnings beat — stock sold off (sell-the-news reaction).
+Positive price momentum.
▼ The bearish case
−Negative session, down 1.5%.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish
The latest catalyst moved the balance toward the bulls — the hollow tick marks where it sat before.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 29, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Ligand raises full-year 2026 EPS guidance to $9.50-$9.75 on 51% Q3 royalty revenue growth.
Filings2026-10-29-1.5%
Ligand Pharmaceuticals Incorporated (LGND) filed a new 8-K on October 29, 2026. The audit found no details of what was disclosed in the filing.
Material / Earnings2026-10-28+2.3%
Ligand Pharmaceuticals Incorporated (LGND) moved +2.30% from $311.62 to $318.78 on 2026-10-28, reaching a new 30-day high. We checked news, earnings announcements, analyst updates, filings, and corporate actions — no company-specific catalyst was found ahead of the move.
News2026-10-27+1.1%
Ligand's senior management will present at UBS Global Healthcare Conference in November.
Ligand Pharmaceuticals rose 2.67% to $314.59 intraday, though a live web search indicates the stock is actually down ~1.32% on the session and has fluctuated between $303.93 and $314.59. No major catalyst was identified in today's news; the stock may be recovering from an earlier intraday dip. Volume of 133,617 shares (54% of typical for this hour) is below average.
Material / Earnings2026-10-20+3.1%
Ligand Pharmaceuticals Incorporated (LGND) moved +2.74% from $298.22 to $306.40 on 2026-10-20. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average.
News2026-10-15+1.2%
Ligand scheduled Q3 2026 earnings release for October 29, 2026.
Material / Earnings2026-10-13-2.4%
Ligand Pharmaceuticals Incorporated (LGND) moved -2.51% from $311.33 to $303.53 on 2026-10-13. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, indicating the move occurred on routine trading activity.
Upcoming catalysts & outlook
Next earnings
2026-10-29
in 0 days
Earnings Release (est.)
2027-01-28
High impact
Thesis shift
Neutral / Mixed
bearish signal
Risk level
Low
from change events
Frequently asked questions about LGND
Why did LGND stock move?
LGND fell 1.5% to $314.12. The move is associated with an earnings beat.
How much did LGND stock fall?
LGND lost 1.46% ($4.66) versus the prior close of $318.78, last trading at $314.12 on 0.4× average volume.
When is LGND's next earnings date?
LGND's next earnings report is scheduled for 2026-10-29 — about 0 days away.
What is the analyst price target for LGND?
The consensus analyst price target for LGND is $339.43, about 8.1% above the current $314.12. Over the past 90 days, analysts recorded 0 upgrades, 5 maintains, and 0 downgrades.
How BestStocks tracks LGND
This page is generated automatically by BestStocks' change-detection system after an earnings beat was detected and verified against independent data sources. It draws on 20 tracked change events for LGND, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 29, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
